It’s another Tuesday, and another edition where we discuss the obesity treatment paradigm. The battle to become the next generation of obesity blockbusters is heating up, and we look at two different strategies being pursued by two future upstarts.
Viking Bets On Fewer Injections
Viking Therapeutics is now trying to carve out space not by matching efficacy but by differentiating, with the latest data on its GLP-1/GIP receptor agonist, VK2735, showing that the injectable drug can maintain weight loss with less-frequent, every-two-week dosing.
Investors have been optimistic on VK2735 for months, given strong efficacy data from earlier trials, but some of that has been tempered since due to concerns around perceived elevated treatment-discontinuation rates. The company is also developing an oral version of the injection.
In the Phase I trial, patients took the drug weekly for about five months and then switched to a shot every other week. They kept nearly all of their weight loss, far more than patients who were switched to placebo. The trial also tested a higher weekly dose over a longer period.